Latest Conference Articles

Creatinine's kinetic profile and nonrenal determinants can leave clinicians behind as kidney function declines or recovers in critically ill patients.

Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.

Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.

In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.

Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.

In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.

Christina O'Connor, PharmD, advises at least 2 g ceftriaxone every 24 hours and considering alternatives to ertapenem in select critically ill patients.

Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

At issue is whether faster clearance of unbound drug shortens free time above the minimum inhibitory concentration, a question with substantial literature and strong opinions on both sides.

Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.

Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.

Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.

Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.

A lipidologist outlines how PREVENT, coronary calcium scoring, and restored LDL-C targets guide personalized lipid therapy and where pharmacists fit in.

When even federal guidance sparks debate, an expert advises pharmacists to consider the source and point patients to long-standing healthful eating.

From red meat to 'big and fluffy' LDL, a lipid expert unpacks fat and cholesterol misconceptions that persist among patients and clinicians.

Validating patient concerns and then reframing them around stroke prevention can help pharmacists counsel patients who worry that statins harm memory.

In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.

Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.

Alexander Turchin, MD, MS, recommends shared decision-making, time-limited lifestyle trials, and gentle persistence to move patients toward statins.

A lipidologist traces patient fears to 2012 FDA label language and reviews observational and randomized data showing no cognitive harm from statins.

In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.

An expert explains why plant-based cooking oils remain the NLA's recommendation for patients at cardiovascular risk, despite new federal advice.

Pharmacists can prompt once-in-a-lifetime Lp(a) testing, reinforce statin adherence, and put muscle aches in context, according to the NLA president.

An expert outlines the new emphasis on protein, whole grains, and added sugars in the guidelines—and why some shifts call for careful counseling

Lp(a) guidance trailed low-density lipoprotein (LDL) cholesterol by decades, but the NLA, ESC, EAS, and now ACC/AHA advise testing all adults at least once, says Dinesh Kalra, MD.